Search
Arizona Paid Clinical Trials
A listing of 1697 clinical trials in Arizona actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1429 - 1440 of 1697
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Popular Cities
Arizona is currently home to 1697 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Birth Control Clinical Research Study
Recruiting
Living with obesity and looking for a birth control option that is right for you? Clinical trials are now enrolling women with a body mass index (BMI) of 30 or more in the area to help study a potential new progestin-only contraceptive patch. Participating in research studies can help advance birth control options. Don’t let financial stress hold you back. All study-related assessments, care, and study patch are available at no cost. You may also be reimbursed for study-related travel.
Conditions:
Obesity
Overweight
Overweight and Obesity
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Study of INBRX-109 in Conventional Chondrosarcoma
Recruiting
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/09/2025
Locations: Mayo Clinic Cancer Center, Phoenix, Arizona
Conditions: Conventional Chondrosarcoma
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
Recruiting
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including Merkel Cell Carcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: HonorHealth, Scottsdale, Arizona
Conditions: Advanced Solid Tumors, Merkel Cell Carcinoma
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
Recruiting
This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 in patients with advanced or metastatic solid tumors. ODC-IL2 is a conditionally activated IL-2 prodrug and will be administered as a single agent via intravenous infusion on Days 1 and 15 of a 28-day cycle. Up to approximately 50 patients will be enrolled in this study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: HonorHealth, Scottsdale, Arizona
Conditions: Advanced Solid Tumors, Metastatic Solid Tumors
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Recruiting
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/06/2025
Locations: Mayo Clinic in Arizona, Phoenix, Arizona
Conditions: High-grade Glioma, WHO Grade Ⅳ Glioma
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
Recruiting
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN).
The study will be conducted in 2 sequential parts. Up to 36 subjects diagnosed with IFALD will be enrolled in the study, of which up to 18 subjects will be enrolled in each of the 2 parts and randomized (2:1) t... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/05/2025
Locations: Mayo Clinic Scottsdale Campus, Scottsdale, Arizona
Conditions: Intestinal Failure Associated Liver Disease
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Recruiting
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Arizona Oncology, Tucson, Arizona
Conditions: TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
ORB-021 In Patients With Advanced Solid Tumors
Recruiting
The goal of this clinical research study is to determine if an investigational new drug, named ORB-021, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor.
The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors.
There are three phases to this study: screening, treatment and end of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Honor Health Clinical Research, Scottsdale, Arizona
Conditions: Advanced Solid Tumors Cancer
Comparing Perioperative Education Modalities for ACL Reconstruction on Patient Satisfaction, Self-Efficacy, and Surgical Outcomes
Recruiting
The purpose of this research is to find out whether the way information about surgery is presented to patients affects patient satisfaction, knowledge retention, and surgical outcomes such as anxiety
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
01/02/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona
Conditions: ACL Injury, Anterior Cruciate Ligament Injuries
Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study
Recruiting
This phase II trial studies the clinical outcomes of hypofractionated radiation therapy in patients with diffuse midline gliomas. This study aims to change the way radiation is delivered, from giving 6 weeks of radiation all at once to giving 2 weeks of radiation. This may determine if there is a difference in the outcome of the treatment, and most importantly, the patients' quality of life.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
12/31/2024
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona
Conditions: Diffuse Midline Glioma, H3 K27M-Mutant
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Recruiting
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: The University of Arizona Cancer Center, Tucson, Arizona
Conditions: HNSCC
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
Recruiting
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona
Conditions: Prediabetic State, Atherosclerosis, Metformin